舒血宁注射液对慢性阻塞性肺疾病急性加重期患者血清基质金属蛋白酶-9及组织金属蛋白酶抑制物-1水平的影响

目的观察舒血宁注射液对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)急性加重期患者血清基质金属蛋白酶-9(matrix metalloproteinase,MMP-9)及组织金属蛋白酶抑制物-1(tissueinhibitor of metalloproteinase,TIMP-1)水平的影响。方法 79例COPD急性加重期患者随机分成治疗组39例和对照组40例,两组均给予COPD常规治疗,治疗组在此基础上予舒血宁注射液15mL加入250mL葡萄糖注射液中静脉滴注,每天2次,共14天,治疗前后分别采用肺功能仪测定第1s用力呼气量(FEV1)及用力肺活量(FVC)数值,计算FEV1/FVC%及FEV1占预计值%。ELISA法检测患者血清MMP-9及TIMP-1浓度,并与20名健康体检者的结果进行对照。结果治疗后,治疗组FEV1、FVC、FEV1/FVC%及FEV1占预计值%均较治疗前及对照组显著改善(P<0.05,P<0.01);治疗组血清MMP-9、TIMP-1浓度及MMP-9/TIMP-1值均较治疗前及对照组显著降低(P<0.05,P<0.01);相关性分析表明,血清MMP-9、TIMP-1浓度与FEV1/FVC%呈明显负相关(r分别为-0.677、-0.629,P<0.01),与FEV1占预计值%亦呈明显负相关(r分别为-0.562、-0.661,P<0.01);MMP-9/TIMP-1值与FEV1占预计值%及FEV1/FVC%亦呈明显负相关(r分别为-0.732、-0.891,P<0.01)。结论舒血宁注射液可改善COPD急性加重期患者肺通气功能,其机制之一可能与其降低血清MMP-9、TIMP-1浓度,纠正MMP-9/TIMP-1失衡有关。

Effects of Shuxuening Injection on the Levels of Serum Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Acute Exacerbated Chronic Obstructive Pulmonary Disease Patients

Objective To observe the effects of Shuxuening Injection(SI) on the levels of serum matrix metalloproteinase-9(MMP-9) and tissue inhibitor of metalloproteinase(TIMP-1) in acute exacerbated chronic obstructive pulmonary disease(COPD) patients.Methods Seventy-nine patients with acute exacerbated COPD were randomly assigned to the treatment group(39 cases) and the control group(40 cases).Routine therapies for COPD were given to patients in the control group,while 15 mL SI was given to those in the treatment group by intravenous dripping,twice daily for total 14 days.The forced expiratory volume in one second(FEV1) and forced vital capacity(FVC) were detected by Spirometer.The FEV1/FVC(%) and the FEV1% were calculated.The levels of serum MMP-9 and TIMP-1 were detected using ELISA before and after treatment,and compared with 20 healthy subjects as the control.Results The FEV1,FVC,FEV1/FVC(%),and FEV1% were significantly improved after treatment in the treatment group when compared with before treatment and with the control group(P<0.05,P<0.01).When compared with before treatment and with the control group,the levels of serum MMP-9,TIMP-1,and the ratio of MMP-9/TIMP-1 decreased more significantly in the treatment group after treatment(P<0.01).Correlation analyses showed that obvious negative correlation existed between the levels of serum MMP-9 and TIMP-1 and FEV1/FVC(%)(r=-0.677,-0.629,P<0.01).Obvious negative correlation existed between the levels of serum MMP-9 and TIMP-1 and FEV1%(r=-0.562,-0.661,P<0.01).Furthermore,obvious negative correlation also existed between the ratio of MMP-9/TIMP-1 and FEV1%,as well as FEV1/FVC(%)(r=-0.732,-0.891,P<0.01).Conclusions SI could improve the pulmonary ventilation function of acute exacerbated COPD patients.One of its mechanisms might be correlated with lowering the serum levels of MMP-9 and TIMP-1,and correcting the imbalance of MMP-9/TIMP-1.